Intellia Therapeutics, Inc.
NTLANasdaq
$11.38
↓ -4.1%Jul 17 close · end-of-day
Price
1Y↓ -4.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3B
Enterprise Value
$971.8M
P/E
—
P/S
20.4
P/B
2.2
EV/EBITDA
—
PEG
—
FCF Yield
-27.0%
Dividend Yield
—
Revenue (TTM)
$66.1M
Net Income (TTM)
-$394.6M
Free Cash Flow (TTM)
-$363.6M
Gross Margin
—
Operating Margin
-636.6%
Net Margin
-597.0%
ROE
-63.5%
ROIC
-135.7%
Debt / Equity
—
Net Cash
$376.0M
Return 1Y
-3.9%
Company profile
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.
- CEO
- John M. Leonard
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 600
- Headquarters
- Massachusetts
- Website
- intelliatx.com
Management & directors
- Dulac Edward J IiiEVP, Chief Financial Officer
- Dube Michael PVP, Chief Accounting Officer
- Basta JamesEVP, General Counsel
- Clark ElianaEVP, Chief Technical Officer
- Leonard John M.President and CEO
- Lebwohl DavidEVP, Chief Medical Officer
- Schultes Birgit CEVP, Chief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
NTLA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15.0M↓ -9.5%
Diluted EPS-$0.81↓ -26.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$136.6M | -$267.9M | -$458.2M | -$515.3M | -$534.3M | -$441.0M |
| Net income | -$134.2M | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
| Diluted EPS | -$2.40 | -$3.78 | -$6.16 | -$5.42 | -$5.25 | -$3.81 |
| Operating cash flow | -$49.9M | -$225.0M | -$333.3M | -$394.1M | -$348.9M | -$394.7M |
| Free cash flow | -$53.5M | -$237.8M | -$346.8M | -$408.1M | -$354.7M | -$395.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -235.5% | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Net margin | -231.5% | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $9.1M | $12.9M | $16.6M | $14.2M | $13.8M | $23.0M | $15.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$139.0M | -$144.8M | -$136.4M | -$120.8M | -$110.0M | -$111.5M | -$98.7M | -$100.5M |
| Net income | -$147.0M | -$135.7M | -$128.9M | -$114.3M | -$101.3M | -$101.3M | -$95.8M | -$96.2M |
| Diluted EPS | -$1.52 | -$1.34 | -$1.27 | -$1.10 | -$0.98 | -$0.92 | -$0.81 | -$0.81 |
| Operating cash flow | -$58.2M | -$84.8M | -$85.2M | -$148.9M | -$99.6M | -$76.9M | -$69.3M | -$117.3M |
| Free cash flow | -$59.2M | -$86.1M | -$86.2M | -$149.7M | -$99.9M | -$76.9M | -$69.4M | -$117.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1998.6% | -1589.0% | -1059.9% | -726.6% | -772.2% | -808.9% | -428.9% | -668.1% |
| Net margin | -2112.6% | -1489.5% | -1001.2% | -687.6% | -710.8% | -735.2% | -416.2% | -639.5% |
Company news
Jul 9, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Dulac Edward J III· EVP, Chief Financial Officer | Sale | 4,677 | $18.00 | $84,186.00 | filing |
| 2026-07-01 | Dube Michael P· VP, Chief Accounting Officer | Sale | 2,641 | $16.78 | $44,315.98 | filing |
| 2026-06-09 | Keresty Georgia | Award | 9,200 | $0.00 | $0.00 | filing |
| 2026-06-09 | GOODMAN JESSE | Award | 9,200 | $0.00 | $0.00 | filing |
| 2026-06-09 | Cohen Fred E | Award | 9,200 | $0.00 | $0.00 | filing |
| 2026-06-09 | CHASE WILLIAM J | Award | 9,200 | $0.00 | $0.00 | filing |
| 2026-06-09 | Bhanji Muna | Award | 9,200 | $0.00 | $0.00 | filing |
| 2026-06-09 | Goff Brian | Award | 9,200 | $0.00 | $0.00 | filing |
| 2026-06-09 | Verwiel Frank | Award | 9,200 | $0.00 | $0.00 | filing |
| 2026-03-02 | BASTA JAMES· EVP, General Counsel | Sale | 1,211 | $13.78 | $16,687.58 | filing |
| 2026-03-02 | Clark Eliana· EVP, Chief Technical Officer | Sale | 607 | $13.78 | $8,364.46 | filing |
| 2026-03-01 | Lebwohl David· EVP, Chief Medical Officer | Award | 9,943 | $0.00 | $0.00 | filing |
| 2026-03-01 | LEONARD JOHN M.· President and CEO | Award | 156,400 | $0.00 | $0.00 | filing |
| 2026-03-01 | BASTA JAMES· EVP, General Counsel | Award | 46,080 | $0.00 | $0.00 | filing |
| 2026-03-01 | Dulac Edward J III· EVP, Chief Financial Officer | Award | 61,280 | $0.00 | $0.00 | filing |
| 2026-03-01 | Schultes Birgit C· EVP, Chief Scientific Officer | Award | 39,200 | $0.00 | $0.00 | filing |
| 2026-03-01 | Clark Eliana· EVP, Chief Technical Officer | Award | 7,353 | $0.00 | $0.00 | filing |
| 2026-03-01 | Dube Michael P· VP, Chief Accounting Officer | Award | 17,250 | $0.00 | $0.00 | filing |
| 2026-01-05 | Cohen Fred E | Buy | 150,000 | $9.35 | $1.4M | filing |
| 2026-01-05 | LEONARD JOHN M.· President and CEO | Sale | 34,146 | $9.21 | $314,484.66 | filing |
| 2026-01-05 | Lebwohl David· EVP, Chief Medical Officer | Sale | 11,903 | $9.21 | $109,626.63 | filing |
| 2026-01-05 | BASTA JAMES· EVP, General Counsel | Sale | 10,397 | $9.21 | $95,756.37 | filing |
| 2026-01-05 | Clark Eliana· EVP, Chief Technical Officer | Sale | 9,515 | $9.21 | $87,633.15 | filing |
| 2026-01-05 | Schultes Birgit C· EVP, Chief Scientific Officer | Sale | 8,508 | $9.21 | $78,358.68 | filing |
| 2026-01-05 | Dulac Edward J III· EVP, Chief Financial Officer | Sale | 6,379 | $9.21 | $58,750.59 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.